The drug development cycle continues to be challenging and highly uncertain. Upon reaching the first pivotal dose (e.g. Phase III), 60%of active substances are expected to make it through to market authorisation.
Between different phase success rates were calculated using the CMR methodology. The fate (progressed/terminated) of active substances that entered phase between 2010-2012 were assessed as of 31 December 2015. Displayed are the probability of success to market values, which are a product of the between phase success rates from the start milestone to market.
Source: 2017 CMR Factbook from Clarivate Analytics; Drawn from Annual Survey of New Molecular Entity First Launches / New Medicine Launches 2016. A complete guide to New Molecular Entities (NMEs) launched world-wide. Reproduced with permission.